# Study to Assess the Effect of Macitentan on the Electrocardiogram (ECG) in Healthy Male and Female Subjects

> **NCT02050802** · PHASE1 · COMPLETED · sponsor: **Actelion** · enrollment: 64 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Moxifloxacin 400 mg
- **DRUG:** Macitentan 10 mg
- **DRUG:** Macitentan 30 mg
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02050802
- **Lead sponsor:** Actelion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2011-11
- **Final completion:** 2011-11
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02050802

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02050802, "Study to Assess the Effect of Macitentan on the Electrocardiogram (ECG) in Healthy Male and Female Subjects". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02050802. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*